- Employers: Entry-Level Applicants Are Just About Useless
- Walmart vs. Costco: How Do They Really Compare?
- Tesla Pops on GM Rumor (Update 1)
- Putting a Fingerprint on Every Bullet
- Why Apple Sucks as an Investment, but Amazon Doesn't
Article
Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales
Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.
09:00AM 06/11/13
Article
Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)
In a bubbly year for the biotech sector, these five stocks stand out over the rest.
07:00AM 06/11/13
Article
Monsanto Jumps on China Trade as Farmer Lawsuit Dismissed
Monsanto gained Monday after a U.S. appeals court dismissed a lawsuit filed by organic farmers.
04:05PM 06/10/13
Article
Ampio Blames Shorts But Won't Answer Legitimate Questions About Its Drugs
Ampio attacks critics instead of answering legitimate questions.
12:21PM 06/10/13
Article
Winners And Losers in CLL at ASCO '13
Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.
07:00AM 06/10/13
Article
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
07:00AM 06/07/13
Article
As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel
Amarin's president says company is preparing for FDA advisory panel seeking expansion of fish-oil pill's use.
11:10AM 06/06/13
Article
Aveo's Future Depends on Triple-Negative Breast Cancer
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.
08:00AM 06/06/13
Article
Remember Vertex? Important Cystic Fibrosis Data On Tap Next Week
Successful combination therapy is the key to growing Vertex's cystic fibrosis business to blockbuster status.
07:00AM 06/06/13
Article
Aveo Fires 140 Workers As Punishment For CEO's Incompetence
The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.
11:06AM 06/05/13
Article
Clovis Doubles on Buzz Over Lung Cancer Drug
Surprisingly strong results for a lung cancer drug have helped Clovis double in value today.
01:31PM 06/03/13
Article
Synta's Lung Cancer Drug Struggles to Remain Relevant
A narrowing of the survival benefit plus competition from anti-PD1s makes Synta's ganetespib success a long shot.
09:18AM 06/03/13
Article
Bristol And Merck's Cancer Drugs Won ASCO. Five Slides Explain Why.
The anti-PD-1s are shrinking tumors like no drugs have done before and investors are really excited.
09:09AM 06/03/13
Article
ASCO '13 Live Blog: Prepping for Monday Trading
Charting the drug and biotech stocks which came out ahead at this weekend's ASCO annual meeting, and those that fell behind.
08:00AM 06/03/13
Article
Merck's Anti-PD1 Melanoma Drugs Shrinks Tumors In Half of Patients
More evidence that immune system-boosting drugs are changing the way melanoma is treated.
11:15AM 06/02/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
